Comparison

FES Antibody

Item no. E10-20146
Manufacturer Enogene
Amount 100 ug/100 ul
Quantity options 100 ug/100 ul 100 ug/100 ul 100 ug/100 ul 100 ug 100 ug/100 ul 200 ul 100 ul 100 ul 100 ul 50 ul 100 ug
Category
Type Antibody
Format Liquid
Applications WB, IHC, ELISA
Specific against Human (Homo sapiens)
Host Mouse
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Alias FPS
Similar products FES
Available
Manufacturer - Applications
WB, IHC, ELISA. Not yet tested in other applications. Determining optimal working dilutions by titration test.
Manufacturer - Conjugate / Tag
This antibody is also available with the following conjugates:
AF350, AF405L, AF405M, AF405S, AF488, AF514, AF532, AF546, AF555, AF568, AF594, AF610, AF635, AF647, AF680, AF700, AF750, AF790, APC, AP, Biotin, Cy3, Cy5.5, Cy5, Cy7, FITC, HRP, PE, Magnetic beads (1 um, 2.8 um, 3 um, 4.5 um, 5 um, 10 um, 15 um, 20 um, 30 um, or different size option)
Please contact sales@hoelzel.de for pricing and availability.
Storage Conditions
Store at 4C, for long term storage, store at -20C
Immunogen
Purified recombinant fragment of FES expressed in E. Coli.
Research Area
Autophagy antibody, Cancer, Cardiovascular, Cell Biology, Epigenetics and Nuclear Signaling, Developmental Biologys, Immunology, Drug Discovery Products, Metabolism, Neuroscience, Signal Transduction, Stem Cells
Background
FES (feline sarcoma oncogene) and Fer are the only two members of a unique family of cytoplasmic protein tyrosine kinases. FES and Fer contain a central Src homology-2 (SH2) domain and a carboxy-terminal tyrosine kinase catalytic domain. They are structurally distinguished from other members of cytoplasmic protein tyrosine kinase subfamilies by the presence of amino-terminal Fer/CIP4 homology and coiled-coil domains. FES was originally identified as an oncogene from avian and feline retroviruses. Human c-Fes has been implicated in myeloid, vascular endothelial and neuronal cell differentiation. FES has tyrosine-specific protein kinase activity and that activity is required for maintenance of cellular transformation. Mutations may activate the FES kinase and thereby contribute to cancer. However, recent data strongly suggests that the c-FES protein-tyrosine kinase is a tumor suppressor rather than a dominant oncogene in colorectal cancer.
Recommended Dilutions
WB.1/500 - 1/2000 , IHC.1/200 - 1/1000, ELISA. Propose dilution 1/10000.
Formulation Description
Ascitic fluid containing 0.03% sodium azide.
CiteID
EN0013410

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 ug/100 ul
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close